Simvastatin Vytorin

Ezetimibe/Simvastatin (Vytorin) [Antilipemic/HMG CoA Reductose Inhibitor] Uses H rp cholest olemia Action X Absorption of cholesterol phytost ol w/ HMG-CoA reductase inhibitor Dose 10/10-10/80 mg/d PO w/ cyclosporine or danazol 10/10 mg/d max w/ amio-darone or verapamil 10/20 mg/d max -1- w/ sev e renal insuff Caution [X, -] w/ CYP3A4 inhibitors (Table VI-8), gemfibrozil, niacin >lg/d, danazol, amiodarone, verapamil Contra PRG/lactation livCT Dz, t LFTs Disp Tabs SE HA, GI upset, myalgia, myopathy (muscle pain, weakness, or tendOTiess w/ CK 10 x ULN, rhab-domyolysis), Hep, Infxn Interactions t Risk of myopathy W7 clarithromycin, erythromycin, itraconazole, ketoconazole EMS None OD Sxs unknown symptomatic and supportive... [Pg.161]

Questran, Questran Light, Prevalite) Colesevelam (WelChol) Colestipol (Colestid) Ezetimibe (Zetia) Ezetimibe/Simvastatin (Vytorin)... [Pg.40]

Simvastatin Vytorin (with ezetlmlbe), Zocor Hypolipaemic 43605... [Pg.897]

Metoprolol 1 00 mg by mouth twice daily Hydrochlorothiazide 25 mg by mouth daily Vytorin 10/40 (ezetimibe 10 mg/simvastatin 40 mg) by mouth daily... [Pg.142]

Ezetimibe interferes with the absorption of cholesterol from the brush border of the intestine, a novel mechanism that makes it a good choice for adjunctive therapy. It is approved as both monotherapy and for use with a statin. The dose is 10 mg once daily, given with or without food. When used alone, it results in an approximate 18% reduction in LDL cholesterol. When added to a statin, ezetimibe lowers LDL by about an additional 12% to 20%. A combination product (Vytorin) containing ezetimibe 10 mg and simvastatin 10, 20, 40, or 80 mg is available. Ezetimibe is well tolerated approximately 4% of patients experience GI upset. Because cardiovascular outcomes with ezetimibe have not been evaluated, it should be reserved for patients unable to tolerate statin therapy or those who do not achieve satisfactory lipid lowering with a statin alone. [Pg.120]

December 1998 labeling VYTORIN 10/10 (Schering) Warnings (ezetimibe/simvastatin) July 2004 labeling... [Pg.267]

Oral 500/20, 750/20, 1000/20 mg tablets Vytorin (ezetimibe plus simvastatin)... [Pg.794]

Ezetimibe is a newer dmg that inhibits cholesterol absorption by the G1 tract it reduces LDLc modestly as monotherapy and is used in combination therapy with simvastatin (marketed as Vytorin) to achieve good cholesterol lowering and minimizing... [Pg.1024]

Ezetlmlbe Zetla, Vytorin (with simvastatin) Anti-cholesterol 25434... [Pg.897]

A combination tablet containing ezetimibe, 10 mg, and various doses of simvastatin (10, 20, 40, and 80 mg) has been approved (Vytorin). At the highest simvastatin dose (80 mg), plus ezetimibe (10 mg), average LDL-C reduction was 60%, which is greater than can be attained with any statin as monotherapy. [Pg.262]

HMGRI and additional antihypercholesterolemic agent Lovastatin/niacin (Advicor) Simvastatin/ezetimibe (Vytorin)... [Pg.1195]

No simvastatin Ezetimibe Tablet oral 10 mg 10 mg Vytorin Singapore MSP... [Pg.42]

In dislipilemic coronary patients with claudication, combination therapy with simvastatin 40 mg and ezetimibe (149) 10 mg (trade name of the combination preparation Vytorin) after dinner combined with fenofibrate (Tricor) 160 mg (94) with breakfast brings a significant improvement in walking time to onset of claudication, and time to absolute claudication (see Chapter 1) measured on the treadmill (personal observations). There is also a remarkable improvement of the patient s lipid profile with this combination therapy. [Pg.201]

Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM. IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes Vytorin Efficacy International Trial) comparison of ezeti-mibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008 156(5) 826-32. [Pg.931]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...